UNIQURE NV's ticker is QURE and the CUSIP is N90064101. A total of 1 filers reported holding UNIQURE NV in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $3,014 | -99.7% | 449,112 | +1485.8% | 0.01% | +400.0% |
Q2 2021 | $872,000 | -75.2% | 28,321 | -72.9% | 0.00% | -75.0% |
Q1 2021 | $3,517,000 | -56.1% | 104,400 | -53.0% | 0.00% | -55.6% |
Q4 2020 | $8,019,000 | +586.0% | 221,940 | +647.3% | 0.01% | +800.0% |
Q3 2019 | $1,169,000 | -91.4% | 29,700 | -82.9% | 0.00% | -91.7% |
Q2 2019 | $13,575,000 | +205.9% | 173,700 | +133.5% | 0.01% | +200.0% |
Q1 2019 | $4,438,000 | +50.7% | 74,400 | -75.7% | 0.00% | +33.3% |
Q3 2017 | $2,944,000 | +36.6% | 306,700 | -11.9% | 0.00% | 0.0% |
Q2 2017 | $2,155,000 | -0.3% | 348,100 | -6.9% | 0.00% | 0.0% |
Q1 2017 | $2,162,000 | +53.7% | 374,000 | +48.8% | 0.00% | +50.0% |
Q4 2016 | $1,407,000 | -21.8% | 251,300 | +6.8% | 0.00% | -33.3% |
Q3 2016 | $1,800,000 | +54.8% | 235,350 | +49.2% | 0.00% | +50.0% |
Q2 2016 | $1,163,000 | -52.4% | 157,790 | -23.3% | 0.00% | -60.0% |
Q1 2016 | $2,445,000 | +40.5% | 205,800 | +95.6% | 0.01% | +25.0% |
Q4 2015 | $1,740,000 | – | 105,200 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aquilo Capital Management, LLC | 841,471 | $15,786,000 | 5.69% |
Nantahala Capital Management | 2,901,929 | $54,440,000 | 3.52% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 544,500 | $10,209,000 | 3.27% |
683 Capital Management, LLC | 1,373,600 | $25,768,000 | 1.99% |
PFM Health Sciences, LP | 2,393,311 | $44,899,000 | 1.62% |
Integral Health Asset Management, LLC | 433,000 | $8,123,000 | 1.58% |
Privium Fund Management B.V. | 238,998 | $4,283,000 | 1.56% |
Nantahala Capital Management | 1,000,000 | $18,760,000 | 1.21% |
Henry James International Management Inc. | 89,469 | $1,678,000 | 0.94% |
Altium Capital Management LP | 105,000 | $1,970,000 | 0.72% |